Core Insights - Merck & Co., Inc. is a global healthcare company facing competition from major pharmaceutical companies like Pfizer and Johnson & Johnson [1] - Mohit Bansal from Wells Fargo has set a price target of $150 for MRK, indicating a potential increase of 29.07% from its current price of $116.22 [1][6] Sales Performance - Gardasil vaccine sales dropped by 39% year over year in 2025, totaling $5.2 billion, primarily due to weak demand in China [2][6] - The decline in Gardasil sales is compounded by reduced demand in Japan and other vaccines, with management not expecting a recovery in 2026 [3] Stock Performance - MRK's current stock price is $115.48, reflecting a slight decrease of 0.63% from the previous day, with a market capitalization of approximately $285.5 billion [4][6] - Over the past year, MRK has experienced stock price volatility, with a high of $125.14 and a low of $73.31 [4] Market Activity - Today's trading volume for MRK is 687,521 shares, indicating investor interest and market activity [5]

Core Viewpoint - Merck & Co., Inc. is navigating challenges in the pharmaceutical industry, particularly with its Gardasil vaccine, while maintaining a strong market position and receiving positive ratings from analysts [1][3][4]. Group 1: Stock Performance - Merck's stock closed at $117.11, reflecting a 1.14% increase from the previous close, outperforming major indexes like the S&P 500, Dow, and Nasdaq [2][4]. - The stock has shown resilience despite a prior decline of 5.04%, indicating investor confidence ahead of the upcoming earnings report [2]. Group 2: Financial Outlook - Analysts predict an earnings per share (EPS) of -$0.57 for the upcoming earnings report on April 30, 2026, representing a significant year-over-year decline of 125.68% [2]. - Revenue is expected to increase by 3.09% to $16.01 billion, indicating some growth potential despite challenges [2][4]. Group 3: Product Challenges - Merck's Gardasil vaccine sales dropped by 39% in 2025, primarily due to reduced demand in China, impacting its partnership with Zhifei and halting shipments [3]. - There is no expected rebound in Gardasil sales for 2026, which may continue to pressure Merck's revenue streams [3]. Group 4: Analyst Ratings - Wells Fargo has reaffirmed an "Overweight" rating on Merck, raising the price target to $150, reflecting optimism about the company's future performance [1][4].

Core Viewpoint - Wells Fargo has raised its price target for Merck (MRK) to $150, driven by the potential of sacituzumab tirumotecan (sac-TMT) to replace chemotherapy in various cancer treatments, alongside the growth of KEYTRUDA and a robust pipeline of 80 Phase 3 studies [1] Group 1: Stock Performance and Predictions - Merck's stock has gained 23% over the past year and 8% year-to-date, currently trading below its 52-week high of $125.14 [1] - The Street consensus price target for Merck is $127.22, while Wells Fargo's target of $150 suggests significant upside potential [1] - Achieving a $150 price target would imply a market capitalization exceeding $283.4 billion, necessitating positive late-stage data for sac-TMT and sustained growth for KEYTRUDA [1] Group 2: Key Drivers of Stock Performance - Emerging growth portfolio: WINREVAIR, Merck's treatment for pulmonary arterial hypertension, generated $467 million in Q4 2025, reflecting a 133% year-over-year increase [1] - KEYTRUDA's revenue reached $8.337 billion in Q4 2025, up 6% year-over-year, with new FDA approvals expanding its indications [1] - The potential of sac-TMT to displace chemotherapy in multiple cancer types represents a significant commercial opportunity for Merck's oncology franchise [1] Group 3: Strategic Developments - The FDA awarded sac-TMT a Commissioner's National Priority Voucher, indicating strong regulatory support for its development [1] - A strategic financing agreement with Blackstone Life Sciences has been established to partially fund the development of sac-TMT [1]

In chemoenzymatic production, Moore also noted that a client used Codexis’ ligase to manufacture a 3-kilogram batch of siRNA , which she described as a major achievement.Moore said the company hit a key technical milestone in 2025 by synthesizing 10 grams of a commercially relevant siRNA using full sequential ECO Synthesis and sharing product quality data showing “no quality barriers related to our production technology.” She said Codexis is continuing to scale the platform in 2026, with operations currentl ...

Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the ...

Halozyme Therapeutics Conference Call Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Conference Date**: March 11, 2026 - **Expected Revenue**: $1.7-$1.8 billion for 2026, representing a 22%-30% year-over-year growth [1][2] Key Products Driving Growth - **Main Revenue Drivers**: - **DARZALEX FASPRO**: Leading product with strong growth due to subcutaneous delivery [2] - **VYVGART HYTRULO**: Significant contributor with 100% year-over-year growth, driven by the adoption of the pre-filled syringe [8][10] - **Roche's Perjeta**: Transitioning to subcutaneous delivery, achieving a 52% conversion rate in the U.S. with a target of 60% by 2028 [6][5] Additional Product Opportunities - **Emerging Products**: Four recently launched products (Opdivo, OCREVUS, RYBREVANT, Tecentriq) expected to contribute significantly in 2026 [3][15] - **OCREVUS**: Roche's drug for multiple sclerosis, with a potential market expansion due to subcutaneous delivery, aiming for a $2 billion increase in sales [17][18] - **RYBREVANT**: Johnson & Johnson's lung cancer drug, transitioning from a 5-hour IV infusion to a 5-minute subcutaneous administration, aiming for a $5 billion brand [22][23] Strategic Partnerships and Deals - **New Partnerships**: Three new deals signed at the end of 2025, with expectations for at least three new deals in 2026 [27] - **Current Partner Expansion**: Existing partners are increasing their nominations for new drugs, indicating strong momentum [26] Development Pipeline - **Current Development**: Seven products in development with ENHANZE, including collaborations with argenx and Takeda [30] - **Future Projections**: Expectation of 40 approved or in-development drugs by 2028, with six new ENHANZE phase 1 starts this year [31] Litigation Update - **Merck Litigation**: Ongoing litigation regarding MDASE patents, with Halozyme confident in its position. Positive outcomes in Germany have halted Merck's launch of SubQ Keytruda [34][36] Acquisitions and Technology Expansion - **Recent Acquisitions**: - **Elektrofi**: Acquired for its Hypercon technology, enhancing subcutaneous delivery capabilities [37] - **Surf Bio**: Acquired for a different approach to hyperconcentration, expanding Halozyme's market opportunities [39] - **Market Acceptance**: Increased acceptance of subcutaneous delivery among partners, with expectations for 5-7 launches by the mid-2030s [44] Financial Guidance and Future Outlook - **Long-term Guidance**: Confidence in achieving $1 billion in royalties from Hypercon by the mid-2030s, based on partner plans and market acceptance [43][44] - **Growth Ambitions**: Continued focus on M&A to add assets with recurring royalty-like revenue, aiming for sustained growth [49][50]

In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward- looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.## ContactsHanah Heintzelman Tempus Communications hanah.heintzelman@tempus.comIndustry:- Artificial Intelligen ...

Halozyme Therapeutics Conference Call Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Date**: March 10, 2026 - **Event**: Leerink's Global Healthcare Conference Key Points Recent Acquisitions - Halozyme executed two acquisitions: Elektrofi and Surf Bio, aimed at enhancing subcutaneous drug delivery capabilities [2][4] - The acquisitions are expected to broaden and diversify offerings for partners in the biologics market [2][4] ENHANZE Technology - ENHANZE is a core technology that allows for large volume subcutaneous delivery of biologics, with 10 approved products and multiple in development [7] - The technology enables injections of 5-15 mL in minutes, enhancing patient convenience and treatment adherence [7][17] - The company anticipates signing 1-3 new ENHANZE deals in 2026, driven by increased interest in subcutaneous delivery [15][20] Hyperconcentration Technology - Hyperconcentration technology allows biologics to be concentrated by 3-4 times, facilitating smaller volume injections (2 mL or less) [4][11] - Clinical scale batches are expected to be ready this year, with two partners anticipated to enter Phase 1 testing [13] - The company projects achieving $1 billion in royalty revenue from Hyperconcentration by the mid-2030s [27][29] Market Trends and Growth Drivers - There is a growing recognition among pharmaceutical companies of the competitive advantages of subcutaneous delivery, leading to increased market interest [16][20] - Examples of successful subcutaneous products include Darzalex, VYVGART, and Ocrevus, which have seen significant market growth due to their delivery methods [17][18][19] M&A Strategy - Halozyme is focused on disciplined M&A, targeting opportunities that align with its business model of recurring, royalty-like revenues [21][25] - The company is patient in evaluating potential acquisitions, looking for businesses that complement its growth story [24][25] Financial Performance - In 2025, Halozyme reported a revenue growth of 38% to $1.4 billion, with royalties growing by 52% [38] - A one-time charge related to the Surf Bio acquisition impacted fourth-quarter EPS, but the company expects strong growth moving forward [38][39] Legal Matters - Halozyme is involved in litigation against Merck for patent infringement related to its Mdase patents, with potential for damages and injunctive relief [45][46] - The company does not expect significant impact from this litigation on its current projections [45] Future Outlook - The company anticipates doubling the number of commercialized and development products from about 20 to 40 by 2028 [54] - Strong growth is expected from existing products, including Darzalex, VYVGART, and RYBREVANT, which is projected to become a significant contributor due to its subcutaneous formulation [55][57] Regulatory Environment - Halozyme is monitoring the implications of the IRA (Inflation Reduction Act) on its products, expecting minimal impact due to the nature of its drug indications [33][36] Conclusion - Halozyme is positioned for significant growth through its innovative technologies, strategic acquisitions, and a strong market presence in subcutaneous drug delivery. The company is optimistic about its future prospects and continues to explore opportunities for expansion while maintaining a disciplined approach to M&A.

Exelixis (NasdaqGS:EXEL) 2026 Conference March 10, 2026 10:40 AM ET Company ParticipantsAndrew Peters - SVP of Strategy and Investor RelationsEmily Shtulman - VP of Targeted OncologyEmily ShtulmanMorning, everyone. My name is Emily Shtulman. I'm a Vice President here on the Targeted Oncology team at Leerink, and I'm super happy to have with me Andrew Peters, senior Vice President of Strategy and Investor Relations at Exelixis. Thanks so much for being with us today.Andrew PetersYeah, happy to be here.Emily ...

Summary of Moderna FY Conference Call (March 10, 2026) Company Overview - **Company**: Moderna (NasdaqGS:MRNA) - **Fiscal Year**: 2025 - **Key Highlights**: Strong execution across revenue and cost management, significant progress in product pipeline Financial Performance - **Revenue**: $1.9 billion for FY 2025, at the high end of guidance range [2] - **Cost Reduction**: Achieved over $2 billion in cost savings, exceeding the $1 billion target set for 2025 [3] - **Cash Balance**: Ended 2025 with a cash balance of $8.1 billion, including $600 million from a credit facility [3] Product Pipeline Developments - **COVID-19 Vaccines**: - Spikevax approved for pediatric use (ages 6 months to 5 years) [4] - Positive data from Phase 3 flu vaccine study, application filed in the U.S. and other territories [4] - **Cancer Pipeline**: - Intismeran in Phase 3 for adjuvant melanoma, fully enrolled renal cell carcinoma study [4] - **Rare Diseases**: Fully enrolled study in PA, expecting readout in 2026 [42] Revenue Growth Projections - **2026 Guidance**: Up to 10% revenue growth expected, driven by: - Continued penetration of Spikevax in the U.S. (24% market share) [5] - Strategic partnerships with the U.K., Canada, and Australia, expected to generate $1 billion in international revenue [11] - **U.S. Sales Decline**: Anticipated decline in U.S. sales from $1.2 billion to $1 billion (20% decline) [11] Combination Vaccine Opportunities - **Flu-COVID Combination**: - Positive CHMP opinion received, expected approval in Europe later in 2026, contributing to revenue in 2027 [12] - Anticipated strong demand from single-payer systems internationally due to cost-effectiveness [15] - **U.S. Market**: Ongoing discussions with the FDA regarding the combination vaccine filing [13] Oncology Market Potential - **Adjuvant Melanoma**: - Multibillion-dollar market opportunity, with a 50/50 partnership with Merck [22] - Positive Phase 2 data with a hazard ratio of 0.51, aiming for similar or better results in Phase 3 [20] - **Future Indications**: Potential synergism with Keytruda, ongoing studies in various cancer types [24] Operating Expenses and Break-even Analysis - **R&D Spending**: Anticipated decrease in cash costs to $3.5 billion-$3.7 billion by 2027, with a need for revenue in that range to break even [36] - **Growth Drivers**: Expected contributions from European market openings and new partnerships in Latin America and Asia-Pacific [37] Rare Disease Program - **Partnership with Recordati**: Expected milestone payments of $160 million and tiered royalties based on sales for the PA program [42] Conclusion - **Outlook**: Exciting year ahead with multiple product approvals and significant growth opportunities in both existing and new markets [43]